ASH Annual Meeting and Exposition 2021
Advertisement
The chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel) significantly improved event-free ...
According to results from the phase III BELINDA trial, patients with relapsed/refractory aggressive B-cell non-Hodgkin ...
The chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel) demonstrated significant and ...
At more than three years of follow-up, most patients with chronic lymphocytic leukemia (CLL) who were treated with a ...
According to the presentation at the 2021 American Society of Hematology Annual Meeting, real-world patients with ...
Pivotal trials that supported Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell ...
Treatment with the investigational injectable hepcidin mimetic rusfertide effectively controlled levels of hematocrit ...
According to results from a phase I/II study, more than 90% of older and high-risk patients with newly diagnosed acute ...
First-line treatment with the autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy axicabtagene ...
In a single-arm phase I/II study, infusion with CT103A, a novel fully human B-cell maturation antigen (BCMA)-targeted ...
Chimeric antigen receptor (CAR) T-cell therapy is a potentially life-saving option for patients with hematologic ...
According to results from the phase III BELINDA trial, patients with relapsed/refractory aggressive B-cell non-Hodgkin ...
According to findings from the REGARDS trial, peripheral blood cytopenias may be associated with a higher risk of ...
According to a poster presentation at the 2021 American Society of Hematology, prescribing chemotherapy is not a ...
According to results from the ASCEMBL trial, asciminib was superior to bosutinib in inducing major molecular responses ...
For patients with chronic myeloid leukemia (CML), treatment with tyrosine kinase inhibitors (TKIs) has increased the ...
According to three-year follow-up data from the ASCEND trial, patients with relapsed/refractory chronic lymphocytic ...
Zanubrutinib Plus Venetoclax Well-Tolerated, Effective as First-Line Therapy for CLL/SLL With Del17p
Preliminary data from a nonrandomized arm of the SEQUOIA trial, presented at the 2021 Annual Meeting of the American ...Although individuals older than 80 years make up more than 20% of cases of chronic lymphocytic leukemia (CLL), this ...
According to a study presented at the 2021 American Society of Hematology Annual Meeting, frontline treatment with ...
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.